Pretreatment With Mono or Dual Pulmonary Hypertension-Targeted Medical Therapy in Patients Undergoing Balloon Pulmonary Angioplasty
CHEST · 2026-11 · 170 (5) · 1555-1564
DOI: 10.1016/j.chest.2026.04.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift CHEST, 2026-11. Verfasst von Diederik P Staal und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Angioplasty, Balloon, Pulmonary Embolism, Antihypertensive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cilag AG.
Abstract (Originalsprache)
BACKGROUND: Pretreatment with pulmonary hypertension (PH)-targeted medical therapy has been shown to reduce balloon pulmonary angioplasty (BPA) complications in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Data collected in the Dutch BPA registry allowed for comparison between mono and dual PH-targeted medical pretreatment in patients undergoing BPA. RESEARCH QUESTION: Does pretreatment with dual PH-targeted medical therapy lead to fewer BPA complications and improved clinical outcomes in comparison with monotherapy? STUDY DESIGN AND METHODS: This study included all consecutive patients with CTEPH who underwent BPA after pretreatment with either mono or dual therapy in The Netherlands. Periprocedural BPA complications were assessed in addition to treatment strategy, clinical parameters, and pulmonary hemodynamics at diagnosis, first BPA, and 6-month follow-up. RESULTS: A total of 169 patients with CTEPH (53% female; mean age ± SD, 66 ± 12 years; 65% World Health Organization functional class III/IV; mean pulmonary artery pressure ± SD, 44 ± 12 mm Hg; pulmonary vascular resistance [PVR] ± SD, 7.7 ± 4.3 Wood units) were included. Of the patients, 93 (55%) received pretreatment with monotherapy and 76 (45%) received pretreatment with dual PH-targeted medical therapy. On a per-BPA session basis, patients pretreated with dual therapy experienced fewer BPA-related thoracic complications (8.4% vs 19.6%; P < .001) than those pretreated with monotherapy. When corrected for center, age, PVR and multiple BPA sessions per patient, independent predictors of thoracic BPA complications were higher logarithmic N-terminal prohormone brain natriuretic peptide (OR, 1.40; 95% CI, 1.07-1.83; P = .01), higher right atrial pressure (OR, 1.09; 95% CI, 1.02-1.17; P = .01), and mono PH-targeted medical pretreatment (OR, 3.33; 95% CI, 1.43-7.69; P = .005). Between baseline and 6-month follow-up, patients pretreated with dual PH-target medical therapy showed significantly greater improvement in 6-minute walking distance, cardiac index, and PVR. INTERPRETATION: This study demonstrates that pretreatment with dual PH-targeted medical therapy was associated with lower (thoracic) periprocedural BPA complications rates. Additionally, clinical outcomes were significantly better in those pretreated with dual PH-targeted medical therapy compared with monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
- Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Radiology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
- Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands; Department of Pulmonary Medicine, OLVG, Amsterdam, The Netherlands.
- Department of Pulmonary Medicine, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Förderung
- Cilag AG
Zitieren
APA
Staal, D. P., Lely, R. Y., Breuning, A. M., van Thor, M. C. J., Peper, J., Nossent, E. J., van Kuijk, J. P., Aman, J., van den Heuvel, D., Van Es, J., Vonk-Noordegraaf, A., Boerman, S., Bogaard, H. J., Mager, J. J., Beijk, M. A. M., & Post, M. C. (2026). Pretreatment With Mono or Dual Pulmonary Hypertension-Targeted Medical Therapy in Patients Undergoing Balloon Pulmonary Angioplasty. CHEST, 170(5), 1555-1564. https://doi.org/10.1016/j.chest.2026.04.048
Vancouver
Staal DP, Lely RY, Breuning AM, van Thor MCJ, Peper J, Nossent EJ, et al. Pretreatment With Mono or Dual Pulmonary Hypertension-Targeted Medical Therapy in Patients Undergoing Balloon Pulmonary Angioplasty. CHEST. 2026;170(5):1555-1564. doi:10.1016/j.chest.2026.04.048
BibTeX
@article{Staal2026,
author = {Staal, Diederik P and Lely, Rutger Y and Breuning, Aleid M and van Thor, Mitch C J and Peper, Joyce and Nossent, Esther J and van Kuijk, Jan-Peter and Aman, Jurjan and van den Heuvel, Daniel and Van Es, Josien and Vonk-Noordegraaf, Anton and Boerman, Sanne and Bogaard, Harm Jan and Mager, Johannes J and Beijk, Marcel A M and Post, Martijn C},
title = {Pretreatment With Mono or Dual Pulmonary Hypertension-Targeted Medical Therapy in Patients Undergoing Balloon Pulmonary Angioplasty},
journal = {CHEST},
year = {2026},
volume = {170},
number = {5},
pages = {1555--1564},
doi = {10.1016/j.chest.2026.04.048}
}
EUVIMED